

LC-MS/MS IDENTIFICATION OF OZANIMOD DEGRADATION PRODUCTS AND DEVELOPMENT OF A GREEN HPLC METHOD FOR IMPURITY QUANTIFICATION

RAJESH VARMA B, USHA RANI N, PRASADARA OP.T.S.R.K, REKHA K, SREENIVASA RAO B

References:

1. Cohen J. A., Comi G., Arnold D. L., Bar-Or A., Selmaj K. W., Steinman L., Havrdova E. K., Cree B. A., Montalban X., Hartung H. P., Huang V., Frohna P., Skolnick B. E., Kappos L. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. *Mult.Scler.* **2019**, 25(9), 1255-1262. <https://doi.org/10.1177/1352458518789884>.
2. Tran J. Q., Hartung J. P., Peach R. J., Boehm M. F., Rosen H., Smith H., Brooks J. L., Timony G. A., Olson A. D., Gujrathi S., Frohna P. A. Results from the First-in-Human Study with Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator. *J. Clin.Pharmacol.* **2017**, 57(8), 988-996. <https://doi.org/10.1002/jcph.887>.
3. William J. S., Feagan G., Wolf C., HaensD., Severine Vermeire, Stephen B. H., Subrata Ghosh., Heather Smith., Matthew Cravets., Paul A. F., Richard Aranda., Sheila Gujrathi., Allan Olson.Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.*N. Engl. J. Med.* **2016**, 374 (18), 1754–1762. <https://doi.org/10.1056/NEJMoa1513248>
4. Gianna Melillo.FDA Approves Ozanimod for Patients With RMS, **2020**, <https://www.ajmc.com/view/fda-approves-zeposia-ozanimod-for-patients-with-rms>
5. U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis". Bristol-Myers Squibb Company (Press release). March 26, 2020. Retrieved March 26, 2020.
6. Juif P. E., Kraehenbuehl S., Dingemans J. Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. *Expert.Opin.Drug.Metab.Toxicol.* **2016**, 12(8), 879–895. <https://doi.org/10.1080/17425255.2016.1196188>
7. Claudio Cianferotti., Giuseppe Barreca., Venkatesh Bollabathini., Luca Carcone., Damian Grainger., Samantha Staniland., Maurizio Taddei.Enantioselective Synthesis of Ozanimod, the Active Pharmaceutical Ingredient of a New Drug for Multiple Sclerosis.*Eur. J. Org. Chem.* **2021**,12,1924–1930. <https://doi.org/10.1002/ejoc.202100058>
8. Sekhar Surapaneni., Usha Yerramilli., April Bai., Deepak Dalvie., Jennifer Brooks., Xiaomin Wang., Julie SelkirkV., Yingzhuo Grace Yan., Peijin Zhang., Richard Hargreaves., Gondi Kumar., Maria Palmisano., Jonathan Q. T.Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulators.*Drug.Metab.Dispos.***2021**,49, 405–419. <https://doi.org/10.1124/dmd.120.000220>
9. Nabil Al-Zaqri., PooventhiranT., JagadeeswaraRaoD., Ali Alsalmeha., Ismail Warade., Renjith Thomas. Structure, conformational dynamics, quantum mechanical studies and potential biological activity analysis of multiple sclerosis medicine ozanimod.*J. Mol. Struct.* **2021**,1227, 129685.<https://doi.org/10.1016/j.mol-struct.2020.129685>
10. Jonathan Q. T., Jeffrey P. H., Allan D. O., Boaz Mendzelevski., Gregg A. T., Marcus F. B., Robert J. P., Sheila Gujrathi., Paul A. F.Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.*Clin.Pharmacol.Drug. Dev.* **2017**, 7(3), 263-276. <https://doi.org/10.1002/cpdd.383>
11. Jonathan Q. T.,Peijin Zhang., Atalanta Ghosh.,Liangang Liu., Mary Syto., Xiaomin Wang., Maria Palmisano.Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.*Adv. Ther.* **2020**, 37, 4381–4395.<https://doi.org/10.1007/s12325-020-01473-0>
12. ICH Guideline: Stability testing of new drug substances and products, Q1A (R2), Current Step 4 version, 6 February 2003.
13. Rajesh V. B., Sreenivasa R. B., Maruthi V. N. R. K., Varaprasad R. M. Assessment of gas chromatography methodology approach for the trace evaluation of carcinogenic impurity. methyl chloride, in trimetazidine dihydrochloride. *Ann. Pharm. Fr.* **2023**, 81, 64-73.<https://doi.org/10.1016/j.pharma.2022.06.012>
14. Varma B. H. R., Rao B. S.Gas Chromatography-Head Space-Mass Spectrometry Sensor based Quality Control of Dobutamine Hydrochloride Bulk Material for a mutagenic impurity, 2-bromopropane. *Res. J. Chem. Environ.* **2023**, 27, 54-61.<https://doi.org/10.25303/2702rjce054061>
15. Rajesh V. B., Battula S. R., Kapavarapu M. V. N. R., Mandapati V. R.A novel Rivaroxaban degradation impurity detection by RP-HPLC extraction by preparative chromatography, and characterization by LC-

- MS, NMR and FT-IR: Analysis of novel impurity in batch samples and tablets of Rivaroxaban. *Rasayan. J. Chem.* **2022**, 15, 2373-2381. <https://doi.org/10.31788/RJC.2022.1547008>
16. ICH Guideline. Validation of analytical procedures: text and methodology Q2 (R1), Current Step 4 Version, 2005.
17. Murali Krishnam Raju P., Shyamala P., Venkata Narayana B., Dantuluri H. S. N. R., Bhupatiraju R. V. A fast, validated UPLC method coupled with PDA-QDa detectors for impurity profiling in betamethasone acetate and betamethasone phosphate injectable suspension and isolation, identification, characterization of two thermal impurities. *Ann. Pharm. Fr.* **2022**, 80(6), 837-852 <https://doi.org/10.1016/j.pharma.2022.03.003>
18. Rajesh Varma Bhupatiraju, Battula Sreenivasa Rao. Gas Chromatography-Head Space-Flame Ionization Sensor based assessment of four residuary solvents in rivaroxaban bulk medication. *Res. J. Pharm. Technol.* **2022**, 15(11), 5158-5163. <https://doi.org/10.52711/0974-360X.2022.00868>
19. Rajesh Varma Bhupatiraju., Srinivasa Kumar B., Pavani Peddi., Venkata Swamy Tangeti. An effective HPLC method for evaluation of process related impurities of Letemovir and LC-MS/MS characterization of forced degradation compounds. *J. Chem.Metrol.* **2023**, 2(2), 181-198. <https://doi.org/10.25135/jcm.98.2311.2975>
20. Rajesh Varma Bhupatiraju., Bikshal Babu Kasimala., Lavanya Nagamalla., Fathima Sayed. Structural evaluation of degradation products of Loteprednol using LC-MS/MS: Development of an HPLC method for analyzing process-related impurities of Loteprednol. *Anal. Sci. Technol.* **2024**, 37(2), 98-113. <https://doi.org/10.5806/AST.2024.37.2.98>
21. Rajesh Varma Bhupatiraju., Srinivasa Kumar B., Venkata Swamy Tangeti., Kandula Rekha., Fathima Sayed. LC and LC-MS/MS Studies for Identification and Characterisation of Related Substances and Degradation Products of Abrocitinib. *Toxicol. Int.* **2024**, 31(2), 321-334. <https://doi.org/10.18311/ti/2024/v31i2/36370>
22. Rajesh Varma Bhupatiraju., Pavani Peddi., Subhashini Edla., Kandula Rekha., Bikshal Babu Kasimala. Green Analytical Approach for HPLC Method Development for Quantification of Sorafenib and Its Pharmacopeia Impurities: LC-MS/MS Characterization and Toxicity Prediction of Stress Degradation Products. *Sep. Sci. Plus.* **2024**, 7(9), 202400106, <https://doi.org/10.1002/sscp.202400106>.